You are here: Industry Insights > colorectal cancer

News List

When and How to Screen for Colorectal Cancer? New NCCN Patient Guideline Explains Latest Timing and Approaches prnasia
December 02, 2021
The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Colorectal Cancer Screening.
CUHK Develops a Novel Faecal Test that can Detect Polyps and Early Colon Cancers with Sensitivity Over 90% prnasia
July 28, 2021
The faecal immunochemical test (FIT) is commonly used to screen for colorectal cancer but it has low sensitivity (around 50%) for early cancer detection and fails to detect polyps.
Keytruda wins NICE backing in MSI-H/dMMR colorectal cancer pharmatimes
May 17, 2021
MSD’s immunotherapy Keytruda has gained UK National Institute for Health and Care Excellence (NICE) backing as a first-line treatment for certain colorectal cancer patients.
NHS England makes Keytruda available for advanced colorectal cancer during pandemic pharmatimes
March 29, 2021
NHS England has reached an interim treatment agreement with MSD for Keytruda for the treatment of certain advanced colorectal cancer patients during the COVID-19 pandemic.
Keytruda scores new EU approval in colorectal cancer pharmatimes
January 27, 2021
MSD’s immunotherapy Keytruda (pembrolizumab) has been approved in the EU for the first-line treatment of metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal cancer.
NICE backs Braftovi for BRAF-positive colorectal cancer pharmatimes
November 25, 2020
The National Institute for Health and Care Excellence (NICE) has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF-positive metastatic colorectal cancer.
Daiichi Sankyo initiates phase 2 study of patritumab deruxtecan in advanced colorectal cancer pharmaceutical-business-review
September 17, 2020
Daiichi Sankyo Company announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), in patients with advanced or metastatic colorectal cancer who are ...
FDA Approves Keytruda for First-Line Treatment of MSI-H/dMMR Colorectal Cancer americanpharmaceuticalreview
July 09, 2020
The Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck) for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Colorectal Cancer Risk Still Up in Patients With Ulcerative Colitis drugs
January 19, 2020
Patients with ulcerative colitis have an increased risk for colorectal cancer and colorectal cancer mortality, according to a study published in the January issue of The Lancet.
Aspirin appears to curb colorectal cancer recurrence and tumor growth worldpharmanews
January 09, 2020
The benefits of a daily aspirin may extend beyond heart health to colorectal cancer treatment, say City of Hope researchers who have found aspirin appears to reduce tumor growth and ...

Previous page 1 2 3 Next page